Company intelligence / Profile preview

Asgard Therapeutics

Lund, Skåne County, Swedenasgardthx.com ↗

Ownership: Private
Employees: ~50
Development stage: Preclinical

Overview

Asgard Therapeutics has demonstrated strong preclinical proof-of-concept for its lead program AT-108, showing potent anti-tumor effects by converting tumor cells into dendritic cells within the body. This approach induces personalized immune responses and complete tumor regression in animal models. The company is preparing AT-108 for clinical trials, with CMC development underway and IND-enabling studies ongoing. First-in-human trials are anticipated following completion of these activities[2][6].

Therapeutic areas: Oncology
Modalities: Gene therapy (viral vector-based)In vivo cell reprogramming technologies[1][2][6][9]
Industry: Biotech

Drug pipeline

1 asset

AT-108

Preclinical

Partnerships

Exothera S.A. (process development & GMP manufacturing partner for viral vectors)[9]Johnson & Johnson Innovation – JJDC, Inc. (investor/partner)[2]RV Invest, Novo Holdings, Boehringer Ingelheim Venture Fund, Industrifonden (investors/partners)[2]

Beyond the preview

Go deeper on Asgard Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Asgard Therapeutics.

Explore the full profile